Based on the Arcus Biosciences Inc stock forecast from 6 analysts, the average analyst target price for Arcus Biosciences Inc is USD 30.86 over the next 12 months. Arcus Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arcus Biosciences Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Arcus Biosciences Inc’s stock price was USD 14.70. Arcus Biosciences Inc’s stock price has changed by -6.37% over the past week, -12.50% over the past month and +5.98% over the last year.
No recent analyst target price found for Arcus Biosciences Inc
No recent average analyst rating found for Arcus Biosciences Inc
Company Overview Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. Read Less
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an inve...Read More
Frequently Asked Questions About Arcus Biosciences Inc (RCUS) Stock
Based on ratings from 6 analysts Arcus Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RCUS's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for RCUS is USD 30.86 over the next 12 months. The maximum analyst target price is USD 44 while the minimum anlayst target price is USD 20.
RCUS stock's Price/Earning ratio is 13.48.
Our analysis grades RCUS stock's Price / Earning ratio at F. This means that RCUS stock's Price/Earning ratio is above 70% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this RCUS may be a overvalued for its sector.
The last closing price of RCUS's stock was USD 14.70.
The most recent market capitalization for RCUS is USD 1.44B.
Based on targets from 6 analysts, the average taret price for RCUS is projected at USD 30.86 over the next 12 months.
This means that RCUS's stock price may go up by +109.91% over the next 12 months.
We can't find any ETFs which contains Arcus Biosciences Inc's stock.
As per our most recent records Arcus Biosciences Inc has 577 Employees.
Arcus Biosciences Inc's registered address is 3928 Point Eden Way, Hayward, CA, United States, 94545.
You can get more information about it from Arcus Biosciences Inc's website at https://www.arcusbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Arcus Biosciences Inc (RCUS) Stock
Based on ratings from 6 analysts Arcus Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RCUS's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for RCUS is USD 30.86 over the next 12 months. The maximum analyst target price is USD 44 while the minimum anlayst target price is USD 20.
RCUS stock's Price/Earning ratio is 13.48.
Our analysis grades RCUS stock's Price / Earning ratio at F. This means that RCUS stock's Price/Earning ratio is above 70% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this RCUS may be a overvalued for its sector.
The last closing price of RCUS's stock was USD 14.70.
The most recent market capitalization for RCUS is USD 1.44B.
Based on targets from 6 analysts, the average taret price for RCUS is projected at USD 30.86 over the next 12 months.
This means that RCUS's stock price may go up by +109.91% over the next 12 months.
We can't find any ETFs which contains Arcus Biosciences Inc's stock.
As per our most recent records Arcus Biosciences Inc has 577 Employees.
Arcus Biosciences Inc's registered address is 3928 Point Eden Way, Hayward, CA, United States, 94545.
You can get more information about it from Arcus Biosciences Inc's website at https://www.arcusbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RCUS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
